Back to top
more

Sunesis Pharmaceuticals, Inc. (SNSS)

(Delayed Data from NSDQ)

$1.37 USD

1.37
331,375

+0.05 (3.79%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.37 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.

Sunesis Pharmaceuticals (SNSS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sunesis (SNSS) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SNSS) Outperforming Other Medical Stocks This Year?

Implied Volatility Surging for Sunesis Pharmaceuticals (SNSS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Sunesis Pharmaceuticals (SNSS) stock based on the movements in the options market lately.

Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SNSS) Outperforming Other Medical Stocks This Year?

Is Sunesis Pharmaceuticals (SNSS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (SNSS) Outperforming Other Medical Stocks This Year?

Sunesis Pharmaceuticals, Inc. (SNSS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals, Inc. (SNSS).

Sunesis Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Sunesis Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Sunesis Pharmaceuticals' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

Options Traders Expect Huge Moves in Sunesis (SNSS) Stock

by Zacks Equity Research

Investors need to pay close attention to Sunesis (SNSS) stock based on the movements in the options market lately.

What's in the Cards for Sunesis (SNSS) This Earnings Season?

by Zacks Equity Research

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals

Swarup Gupta headshot

5 Cancer-Fighting Stocks to Boost Portfolio Gains

by Swarup Gupta

It would pay to invest in these companies which offer current franchises or prospective treatments for the most dreaded of diseases.

Will Sunesis Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Sunesis Pharmaceuticals.

Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up

by Zacks Equity Research

Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.

Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock

by Zacks Equity Research

Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.

Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acorda (ACOR) rides high on earnings and revenue beat in Q4. The company plans the US launch of Inbrija in first-quarter 2019.

Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

by Zacks Equity Research

Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

Sanghamitra Saha headshot

5 Top-Ranked Rising P/E Stocks to Lure Investors

by Sanghamitra Saha

Inside the top-ranked stocks that have been exhibiting rising P/E ratios.

    Indrajit Bandyopadhyay headshot

    5 Biotech Stocks Under $10 Worthy of Investors' Attention

    by Indrajit Bandyopadhyay

    Small biotech stocks are good bets with lower market cap as well as share price.

      Are Options Traders Betting on a Big Move in Sunesis Pharmaceuticals (SNSS) Stock?

      by Zacks Equity Research

      Investors in Sunesis Pharmaceuticals (SNSS) need to pay close attention to the stock based on moves in the options market lately.

        Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric

        by Zacks Equity Research

        Zacks.com featured highlights include MINDBODY, TearLab, Sunesis Pharmaceuticals, Children's Place, Franklin Electric

          Step Beyond Bargain Hunting: 5 Stocks With Rising P/E

          by Zacks Equity Research

          Bet on these top-ranked stocks with rising P/E to realize outsized gains.

            Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4

            by Zacks Equity Research

            Endocyte, Inc. (ECYT) reported a fourth-quarter 2016 loss of 26 cents per share, wider than both the Zacks Consensus Estimate of a loss of 25 cents and the year-ago loss of 23 cents.

              Alexion's sBLA for Soliris Receives FDA Acknowledgement

              by Zacks Equity Research

              Alexion Pharmaceuticals, Inc. (ALXN) announced that the FDA, on Mar 9, has accepted the supplemental Biologics License Application (sBLA) to expand the indication for Soliris